Latest Breaking News On - Markus peters - Page 8 : comparemela.com
VIA optronics AG: VIA optronics Reports Unaudited Second Quarter 2021 Results
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
VIA optronics AG Appoints Dr Markus Peters as Chief Financial Officer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Das Haus vor der Witterung schützen
mittelbayerische.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mittelbayerische.de Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
Fortress Biotech, Inc.May 16, 2021 GMT
Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021
On track to report top-line results from the registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma by year-end 2021
Ended first quarter 2021 with $291.5 million in consolidated cash, cash equivalents and restricted cash
NEW YORK, May 16, 2021 (GLOBE NEWSWIRE) Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced financial results and recent corporate highlights for the first quarter ended March 31,
Aevitas Therapeutics Appoints Markus Peters, Ph.D., M.Sc., as Chief Executive Officer
February 22, 2021 08:00 ET | Source: Aevitas Therapeutics, Inc. Aevitas Therapeutics, Inc.
Catherine Bowes Rickman, Ph.D., FARVO, a leading age-related macular degeneration researcher, appointed to Scientific Advisory Board
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) Aevitas Therapeutics, Inc. (“Aevitas”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company focused on the development of novel gene therapy approaches for complement-mediated diseases, today announced the appointment of Markus Peters, Ph.D., M.Sc., as President and Chief Executive Officer. Dr. Peters was most recently the Chief Operating Officer of Gemini Therapeutics after serving as the Chief Commercial Officer of Agilis Biotherapeutics. Dr. Peters will lead the Company as it advances its proprietary platform designed to deliver engineered, fully functional, shortened comple